Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Aug 11, 2026
Keel Infrastructure (KEEL) Drops -27% as Q2 Earnings Miss and Bitcoin Exit Pressure the Stock

Keel Infrastructure (KEEL) Drops -27% as Q2 Earnings Miss and Bitcoin Exit Pressure the Stock

Key Takeaways

  • Keel Infrastructure (KEEL) shares dropped approximately 27% over the last 30 days, falling from $4.65 on July 10 to $3.40 as of August 10, 2026.
  • The steep decline was triggered by a deeply disappointing Q2 2026 earnings report that revealed a 50% year-over-year revenue decline and a wider-than-expected quarterly loss.
  • Investor sentiment soured as the company's complete exit from U.S. Bitcoin mining operations eliminated a major revenue stream ahead of its still-unproven AI data center transition.
  • Permitting delays at the flagship Panther Creek site in Pennsylvania, combined with a broader risk-off rotation away from pre-revenue development-stage companies, amplified the sell-off.
  • Over the last quarter, KEEL fell roughly 26%, erasing gains from a June rally that briefly pushed shares above $6.60 following addition to the Russell 3000 Index.

Keel Infrastructure's Business Transition and Current Positioning

Keel Infrastructure Corp., formerly known as Bitfarms Ltd., is a New York City-based digital infrastructure and energy company that develops and owns data centers and energy infrastructure purpose-built for high-performance computing (HPC) and artificial intelligence (AI) workloads. The company completed a sweeping strategic transformation in early 2026, rebranding and relocating its corporate domicile to the United States while exiting nearly all legacy Bitcoin mining operations. Keel's portfolio centers on three near-term priority sites — Moses Lake in Washington State, and Sharon and Panther Creek in Pennsylvania — alongside the Sherbrooke project in Québec, Canada. With a development pipeline of 2.2 gigawatts and established grid interconnections in high-demand power markets, Keel positions itself as a pure-play AI infrastructure developer targeting the critical bottleneck in the AI supply chain: available power. The stock trades on both Nasdaq and the TSX and carries a market capitalization of approximately $2.05 billion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

KEEL Stock Performance Over the Past 30 Days and Quarter

KEEL shares experienced a severe drawdown of roughly 27% over the past 30 days, tumbling from a closing price of $4.65 on July 10, 2026, to $3.40 by the August 10 close. The decline was punctuated by multiple single-day double-digit percentage drops, including a 14.9% plunge on July 29 and the 12.4% rout on August 10 following the Q2 earnings release. Over the broader quarterly window, the stock declined approximately 26%, starting from around $4.61 in mid-May. The quarter was marked by sharp volatility: KEEL surged to a high of $6.66 in late June after being added to the Russell 3000 Index, only to give back those gains and more during the July and early August sell-off as macro uncertainty and company-specific headwinds converged.

Drivers Behind the Recent 30-Day Decline

The primary catalyst behind the 30-day decline was the Q2 2026 earnings report released on August 10. Keel reported revenue of just $30.43 million, down 50% year-over-year and well below the consensus estimate of approximately $33.4 million. The loss from continuing operations reached $64 million, or $0.11 per share — nearly double the $0.06 per-share loss analysts had projected. The operating loss ballooned to $141 million, including $63 million in accelerated depreciation tied to mining rig shutdowns at Panther Creek and Scrubgrass, while adjusted EBITDA swung to negative $24 million from positive $7 million in the prior-year quarter. Beyond earnings, the company's ongoing Bitcoin exit continued to pressure the stock. All U.S. cryptocurrency mining operations were fully decommissioned during the quarter, and Keel sold 1,085 Bitcoin for $75 million between April 1 and August 7 — effectively zeroing out what had been the company's primary revenue engine. Meanwhile, permitting delays emerged at Panther Creek, Keel's flagship 350-megawatt campus, where final environmental approvals with Pennsylvania regulators are taking longer than originally anticipated. Although management emphasized that the delays do not affect the planned 2027 power delivery schedule or project economics, the market interpreted the slower timeline as a setback in an already patience-testing transition. Broader macro headwinds, including widened credit spreads and a risk-off rotation away from pre-revenue growth companies, compounded selling pressure across the final weeks of the period. From what I see, these factors converged in a way that made the sell-off particularly sharp.

Quarterly Trajectory and Key Events

Over the full quarterly period, KEEL's trajectory was defined by a sharp rally followed by an even steeper unwind. In June, the stock surged following the company's addition to the Russell 3000 Index and the successful pricing of a $458 million convertible senior notes offering — upsized from an initial $350 million target — which fortified the balance sheet. The company reported $819 million in total liquidity as of August 7, including approximately $698 million in unrestricted cash, funding site development through lease signing and cash SG&A through 2028. However, the broader narrative shifted as investors grew increasingly impatient with the pace of the AI infrastructure pivot. Competitors in the space continued to announce customer lease agreements while Keel remained in negotiations, and the appointment of former Digital Realty executive Ganesh Aiyer as President, though strategically significant, did not immediately translate into signed tenant contracts. The sharp July sell-off reflected mounting concern that Keel's transition timeline — with first revenues not expected until 2027 — leaves the stock exposed to market volatility without near-term catalysts. One thing that stands out is how quickly sentiment can shift in this sector.

What to Monitor for KEEL Ahead

The single most consequential near-term catalyst for KEEL is lease execution. Management has stated it is in active commercial negotiations with multiple prospective tenants — including hyperscalers, AI companies, GPU cloud providers, and large enterprises — across all three priority sites. Any signed lease announcement, particularly one involving an investment-grade counterparty, would represent a significant de-risking event for the stock. On the permitting front, investors should monitor the completion of final environmental approvals at Panther Creek, Sharon, and Moses Lake, with Moses Lake expected to be the first site fully permitted and generating HPC revenue in 2027. The expansion capacity update expected as early as December or January will also be closely watched, as Keel works to convert its 2-gigawatt Pennsylvania pipeline into secured energy service agreements. On the macro side, interest rate trends, credit market conditions, and the regulatory environment for data center development — including ongoing moratorium discussions in certain states — could meaningfully influence both Keel's cost of capital and the pace of industry-wide buildout. With analysts maintaining a consensus Moderate Buy rating and an average price target of approximately $6.25, the gap between current trading levels and Wall Street expectations underscores both the opportunity and the execution risk that lie ahead. I'm watching this closely as the next few quarters unfold.

Integrating AI Tools Into My Research Process

When analyzing volatile situations like the one surrounding KEEL, I often turn to Tickeron’s AI Trading Bots for additional perspective on systematic approaches that remove emotional bias. These tools help me evaluate potential strategies across different market conditions without needing to build everything from scratch. Exploring them has become a regular part of how I cross-check ideas in fast-moving sectors.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: KEEL

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


KEEL in downward trend: 10-day moving average broke below 50-day moving average on July 13, 2026

The 10-day moving average for KEEL crossed bearishly below the 50-day moving average on July 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KEEL as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KEEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for KEEL entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KEEL's RSI Indicator exited the oversold zone, of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where KEEL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for KEEL just turned positive on August 04, 2026. Looking at past instances where KEEL's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KEEL advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .

KEEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KEEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.876) is normal, around the industry mean (7.191). P/E Ratio (0.000) is within average values for comparable stocks, (71.502). KEEL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.206). KEEL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.025). P/S Ratio (8.937) is also within normal values, averaging (146.856).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KEEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are International Business Machines Corp (NYSE:IBM), Accenture PLC (NYSE:ACN), Unisys Corp (NYSE:UIS).

Industry description

The industry, whose total market cap runs into trillions, makes hardware/software that allows data to be stored, retrieved, transmitted, and manipulated on computers. With the ever-increasing relevance of data, the information technology (IT) industry has gained momentous growth over the years, and continues to thrive on innovation. Some of the behemoths in the industry are International Business Machines Corporation, Accenture, and VMware, Inc.

Market Cap

The average market capitalization across the Information Technology Services Industry is 9.29B. The market cap for tickers in the group ranges from 0 to 222.64B. IBM holds the highest valuation in this group at 222.64B. The lowest valued company is ARSC at 0.

High and low price notable news

The average weekly price growth across all stocks in the Information Technology Services Industry was 0%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 52%. IT experienced the highest price growth at 27%, while NABL experienced the biggest fall at -37%.

Volume

The average weekly volume growth across all stocks in the Information Technology Services Industry was -22%. For the same stocks of the Industry, the average monthly volume growth was -1% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 65
Price Growth Rating: 58
SMR Rating: 72
Profit Risk Rating: 93
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
KEEL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry InformationTechnologyServices

Profile
Details
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.